SRR6013530
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.320
- KRAS_SIGNALING_DN+0.310
- HEDGEHOG_SIGNALING+0.240
- WNT_BETA_CATENIN_SIGNALING+0.240
- TNFA_SIGNALING_VIA_NFKB+0.210
- NOTCH_SIGNALING+0.170
- P53_PATHWAY+0.170
- ESTROGEN_RESPONSE_EARLY+0.150
- ESTROGEN_RESPONSE_LATE+0.150
- SPERMATOGENESIS+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.460
- ALLOGRAFT_REJECTION-0.430
- PROTEIN_SECRETION-0.380
- ADIPOGENESIS-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.360
- MYC_TARGETS_V1-0.350
- OXIDATIVE_PHOSPHORYLATION-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-A5DS-01A-11R-A27Q-07 | — | cohortSQ1 | 0.853 |
| 2 | BS_9CA93S6D | Diffuse intrinsic pontine glioma | — | 0.842 |
| 3 | SRR29022832 | — | A | 0.825 |
| 4 | BS_W4DB5RP1 | Diffuse intrinsic pontine glioma | — | 0.823 |
| 5 | MDT-AP-0222 | Med | Medulloblastoma | 0.820 |
| 6 | MNG1257 | — | — | 0.814 |
| 7 | BSR_10_0261_B3_S85 | — | A | 0.809 |
| 8 | MDT-AP-0530 | Med | Medulloblastoma | 0.807 |
| 9 | SRR6013482 | — | cohortA1 | 0.805 |
| 10 | SRR1313116 | — | A | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |